Gino Disciullo

Gino Disciullo is the current director at ClinOne, and they have also held positions at Colorado BioScience Association, Prevacept Infection Control, Inc., Charter Life Sciences, and Research Corporation Technologies. At Prevacept Infection Control, Inc., Gino served as the Chief Executive Officer and a BOD member. There, they helped manufacture the PrevaCept Lock Solution, which has been shown to reduce the risk of sepsis caused by catheters colonized by microbial pathogens. Gino has also been a part of CLS, a life sciences venture capital firm, as a partner since 2006. There, they have invested in medical device, bio-pharmaceutical and healthcare IT companies. Gino's previous experience also includes being a board member for Mid-America Healthcare Investors Network and a scientist for Cytologix (Dako).

Gino Disciullo has a Ph.D. in Immunology/Pathology from Boston University School of Medicine and a BA in Biology from Stonehill College.